Harvard Bioscience (HBIO) Revenue (2010 - 2026)

Harvard Bioscience (HBIO) has reported Revenue for 17 consecutive years, with $22.7 million the latest figure, recorded in Q2 2026.

• On a quarterly basis, Revenue rose 11.13% year-over-year to $22.7 million in Q2 2026; TTM through Jun 2026 was $87.8 million, a 1.06% decrease from a year earlier, with the FY2025 full-year figure at $86.6 million, down 8.06% from the prior year.
• Revenue was $22.7 million for Q2 2026 at Harvard Bioscience, up from $20.8 million in the prior quarter.
• Over five years, Revenue peaked at $30.0 million in Q1 2023 and troughed at $20.4 million in Q2 2025.
• A 5-year average of $25.0 million and a median of $24.5 million in 2024 frame the typical range for Revenue.
• Across the five-year window, Revenue slipped 19.69% in 2024 and gained 11.13% in 2026, its largest moves.
• Over 5 years, Revenue stood at $28.4 million in 2022, then dropped by 0.96% to $28.2 million in 2023, then retreated by 12.78% to $24.6 million in 2024, then retreated by 3.34% to $23.7 million in 2025, then fell by 4.25% to $22.7 million in 2026.
• The last three Revenue figures came in at $22.7 million (Q2 2026), $20.8 million (Q1 2026), and $23.7 million (Q4 2025), per Business Quant data.